Literature DB >> 6224851

Inhibiton of IL 2 production after human allogeneic bone marrow transplantation.

O Azogui, E Gluckman, D Fradelizi.   

Abstract

Bone marrow transplantation (BMT) is currently used to treat patients with severe aplastic anemia or leukemia. Despite the use of an HLA identical sibling donor, however, the survival after BMT is reduced by the occurrence of two major immunologic complications: graft-vs-host disease and a long-lasting immune deficiency responsible for late infections. This immune deficiency could be explained by an imbalance of lymphocyte subpopulations reconstituted after transplant. The aim of the present work was to study the helper function by measuring the production of interleukin 2 (IL 2). This lymphokine is responsible for the amplification of the effector phase of immunity. A consecutive series of 34 patients was tested for IL 2 production after BMT. This production was absent or low in 32 of 34 patients for at least 2 yr after BMT. The mechanism of this low IL 2 production was investigated. Irradiation of patients' lymphocytes in vitro with low dose gamma-rays partially restored the IL 2 production after 6 mo of evolution. The IL 2 production was not restored or was slightly affected by irradiation early after BMT. These results suggest that the lack of immune reconstitution after BMT may be caused by the lack of IL 2-producing cells and/or the increased activity of suppressor cells of the helper function. This suppression is radiosensitive.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224851

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: functional analyses of lymphocytes and correlation with immunophenotypic recovery following transplantation.

Authors:  H Kook; F Goldman; R Giller; N Goeken; C Peters; M Comito; S Rumelhart; M Holida; N Lee; M Trigg
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

2.  Recombinant interleukin 2 therapy in severe combined immunodeficiency disease.

Authors:  R Pahwa; T Chatila; S Pahwa; C Paradise; N K Day; R Geha; S A Schwartz; H Slade; N Oyaizu; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

3.  The clinical and immunological effects of cyclosporin A on patients with rheumatoid arthritis.

Authors:  D M Chang; S F Chiao
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

4.  Relation between the increase of circulating CD3+ CD57+ lymphocytes and T cell dysfunction in recipients of bone marrow transplantation.

Authors:  M Izquierdo; M A Balboa; J M Fernández-Rañada; A Figuera; A Torres; A Iriondo; M López-Botet
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

5.  Analysis of different protein kinase C-dependent events in T cells from allogeneic bone marrow transplantation recipients.

Authors:  M A Balboa; M Izquierdo; F Sánchez-Madrid; J M Fernández-Rañada; M López-Botet
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

6.  Correction of interleukin-2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells.

Authors:  M Linker-Israeli; A C Bakke; F P Quismorio; D A Horwitz
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.